42 results about "Aqueous flow" patented technology

Methods and systems are disclosed for creating an aqueous flow pathway in the trabecular meshwork, juxtacanalicular trabecular meshwork and Schlemm's canal of an eye for reducing elevated intraocular pressure. Some embodiments described apparatus and methods useful in photoablation of tissues. In some embodiments, a photoablation apparatus is used to perforate a tissue, forming an aperture into a space behind the tissue. Gases formed during a photoablation process can be used to pressurize the space behind the tissue to enhance patency of the space. In some embodiments the tissue is the trabecular meshwork of the eye and a wall of Schlemm's canal, and the space behind the tissue is a portion of the lumen of Schlemm's canal. In some embodiments, the method is useful in the treatment of glaucoma by improving outflow from the anterior chamber of the eye into Schlemm's canal, reducing intraocular pressure.

A method and delivery system are disclosed for creating an aqueous flow pathway in the trabecular meshwork, juxtacanalicular trabecular meshwork and Schlemm's canal of an eye for reducing elevated intraocular pressure. Pulsed laser radiation is delivered from the distal end of a fiber-optic probe sufficient to cause photoablation of selected portions of the trabecular meshwork, the juxtacanalicular trabecular meshwork and an inner wall of Schlemm's canal in the target site. The fiber-optic probe may be advanced so as to create an aperture in the inner wall of Schlemm's canal in which fluid from the anterior chamber of the eye flows. The method and delivery system may further be used on any tissue types in the body.

A posterior chamber phakic lens made from an elastomeric, foldable, highly biocompatible and permeable material. The lens has a generally circular optic and a plurality of integrally formed, filament-like haptics. The haptics project posteriorly from the optic and contain a raised feature or ridge that is sandwiched between the posterior iris and the zonules when implanted in an eye. Such a construction has a low vaulting force under compression, is size insensitive, provides for a stable lens once implanted in the eye, helps to avoid pupillary blockage and allows for improved aqueous flow around the natural lens.

A non-aqueous flow cell energy storage device comprises a ionically conductive separator, which separator comprises a polyurethane prepared by curing an isocyanate capped prepolymer, which prepolymer was prepared from a polyol having polycarbonate backbone, wherein the separator may be impregnated with electrolyte salts and/or swelled by an organic solvent.

A treatment process for an aqueous phase which contains oil droplets, possibly of 10-50 nm diameter, in aqueous flow from a hydrocyclone separator, comprises bringing the water into contact with a surface subdivided into areas of differing surface energy and affinity for oil and such that when the surface is submerged in an aqueous phase, oil droplets adhere to it with an apparent contact angle in a range from 90 to 150 degrees. Areas of the surface may reduce their affinity for oil in response to an external stimulus causing controlled release of droplets adhering to the surface. The process may be used to remove oil droplets from water produced by an oil or gas well, after downhole oil water separation or after production at a at a well head, or used to coalesce droplets in such water to a larger size to enable conventional separation.

Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.

Sequences and protocols for treatment of eye conditions by use of RNA interference are disclosed. Target genes are selected from those responsible for aqueous flow or aqueous outflow, while particularly preferred conditions to be treated include glaucoma and uveitis.

The invention provides an aqueous organic flow battery electrolyte. The aqueous organic flow battery electrolyte is composed of an electrolyte compound and a supporting electrolyte solution. The electrolyte compound is composed of an organic electrolyte and a coating material for coating the organic electrolyte. The coating material is an annular molecule with a hydrophilic outer edge, a hydrophobic inner cavity and a cavity. The organic electrolyte is an electrolyte poor in water solubility on its own or a product poor in water solubility after gaining and losing electrons. The invention alsoprovides a preparation method of the aqueous organic flow battery electrolyte. The invention also provides an aqueous organic flow battery. The electrolyte provided by the invention can replace the modification step of the organic electrolyte. The organic electrolyte poor in water solubility is directly applied to the aqueous flow battery, so that the cost of the flow battery is reduced.

An aqueous liquid composition comprising: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or hydrate; (b) a non-ionic surfactant; and (c) a preservative; wherein at least 90 percent of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically acceptable salt or hydrate remains in the composition after storage at 60° C., for 4 weeks. The composition can satisfy the preservative efficacy of US Pharmacopeia 35 (2012). The composition is useful for the treatment of ocular or nasal inflammation of diverse etiology.

An improved posterior chamber phakic intraocular lens (PCP-IOL) having a haptic with a collar, self-adjusting struts, and lens is disclosed. Haptic or lens of the PCP-IOL may include a protected orifice. A disclosed PCP-IOL may be configured to fit anatomy of varying sizes, and may be self-centering; additionally, a PCP-IOL as set forth herein may allow peripheral aqueous flow between anterior and posterior chambers of a patient's eye.

The invention relates to an apparatus for the filtration of aqueous liquid that is capable of effectively removing suspended particles from aqueous liquid during a prolonged period of time without clogging of the particulate filter media and associated pressure build-up. This filtration apparatus comprises: ⋅a filtration chamber comprising an inlet opening that is located near the bottom of the filtration chamber, and an outlet opening that is located near the top of the filtration chamber; ⋅a screen covering the outlet opening of the filtration chamber; ⋅a first dosing unit that is located upstream of the filtration chamber adapted to release water-soluble components into the stream of aqueous liquid that flows from the inlet to the filtration chamber; ⋅a particulate filter media that partially fills the interior of the filtration chamber; ⋅a flow regulator that regulates the flow rate of aqueous liquid through the filtration chamber and that can operate in a high flow rate mode or a reduced flow rate mode; ⋅a timer that controls the flow regulator; wherein the timer is programmed to alternatingly switch the flow regulator from the high flow rate mode to the reduced flow rate mode.

A liquid additive feed system for a pressure controlled fluid flow line, which may include a liquid reservoir, a manifold, a flow line pressure regulation module, a flow controlled inlet line, a flow controlled feed line, and a diffusion interface, which dynamically adjustably delivers a metered dosage of liquid additive into a controlled aqueous flow delivery system.

The invention belongs to the technical field of cosmetics, and discloses an aqueous liquid eye shadow and a preparation method thereof. The aqueous liquid eye shadow comprises a thickening agent, and the thickening agent comprises carbomer, polyacrylate-13, polyisobutene and polysorbate-20. According to the aqueous liquid eye shadow, carbomer, polyacrylate-13, polyisobutene and polysorbate-20 are compounded to serve as the thickening agent, so that the aqueous liquid eye shadow has proper viscosity, the viscosity at normal temperature is about 1250 cp, and the aqueous liquid eye shadow is fresh and not sticky after being used and has excellent skin feeling after being used; and the thickening agent can well disperse and suspend pearl powder, and meanwhile, in the production process, a material body has proper viscosity, few bubbles, high flowability and easiness in filling.

Some embodiments of the invention advantageously leverage the expansion, dilation or by-pass of the Schlemm's canal using adjustable reversible self-expanding eye stents (SES) or eye tension rings (ETRs) of desired sizes to control and improve aqueous flow throughout the range of the uveolymphatic canal. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the Schlemm's canal wall and is at least partially within the canal and/or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the wall and/or elsewhere in the canal. The partial or complete expansion of the canal can be pre-configured based on pre-operative metrology of the Schlemm's canal to a customized and adjustable fit across the various zones within the uveolymphatic canal and based on the patient specific and evolving needs. Additionally, the SES can utilize entry/exit features for by-pass of fluid, varying control of dilation across its shape that may also allow anchoring, repositioning, and retrieval.

Disclosed herein include systems, apparatuses, devices, and methods for introducing one or more components into a fluid. A first fluid and a second fluid can be co-injected into a fluidic channel of a flow cell. In some embodiments, the first fluid and a second fluid are immiscible (e.g. an aqueous buffer and a non-aqueous liquid). In some embodiments, the second fluid is less dense than the first fluid.